CLINICAL AND THERAPEUTIC STUDIES IN HUMAN FILARIASIS

伊维菌素已经在南方的一项公开的医院试验中被显示出来 印度将有效清除患有微丝虫病患者的微丝虫病 班氏丝虫病，一次给药剂量低至25-微克/公斤 口交。伊维菌素第二次盲法安慰剂对照试验 而目前使用的药物二乙基卡马津(DEC)已经 完成了治疗，但没有后续阶段。初步 研究结果表明，伊维菌素和DEC的疗效是 伊维菌素引起的副反应可能 要少得多。这些发现和伊维菌素的单口- 剂量给药模式使其成为一种极好的候选药物 取代DEC成为治疗淋巴癌的首选药物 丝虫病。 因为使用支气管肺泡的长期随访研究 灌洗对TPE患者常规治疗效果的评价 二乙基卡马津(DEC)显示，大约1/3 复发或有持续性低度肺泡炎导致 肺纤维化：三种方案的治疗试验 (常规DEC、长期DEC或DEC+类固醇) 在马德拉斯发起。这项研究将需要大约三年的时间来 纳入预期的75名研究患者。 200名和平队志愿者赴Loa Loa观察 非洲地方病流行地区在经历了三年的 使用每周剂量的安慰剂对照化学预防试验 12月。血清转换率约为15%，但最终分析 的结果还没有完成。

Ivermectin has been shown in an open, in-hospital trial in South India to be effective in clearing microfilaremia in patients with bancroftian filariasis at dosages as low as 25-mcg/kg given once orally. A second, blinded, placebo-controlled trial of ivermectin and the currently used drug, diethylcarbamazine (DEC), has completed its treatment but not follow-up phase. Preliminary findings suggest that the efficacy of Ivermectin and DEC are equivalent and that the side reactions induced by ivermectin may be significantly less. These findings and ivermectin's single-oral- dose mode of administration make it an excellent candidate to replace DEC as the drug of choice for treating lymphatic filariasis. Because long-term follow-up studies employing bronchoalveolar lavage to evaluate patients with TPE treated conventionally with diethylcarbamazine (DEC) have shown that approximately 1/3 relapse or have persistent low-grade alveolitis leading to pulmonary fibrosis, a therapeutic trial of three regimens (conventional DEC, long-term DEC, or DEC + steroids) has been initiated in Madras. The study will require about three years to enroll the anticipated 75 study patients. Observations on 200 Peace Corps volunteers going to Loa loa endemic areas of Africa are concluding after three years of a placebo-controlled chemoprophylaxis trial using weekly doses of DEC. Seroconversion is at approximately 15% but final analysis of the results is not yet complete.